Wave Life Sciences
- Country
- ๐ธ๐ฌSingapore
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 268
- Market Cap
- $704.7M
- Introduction
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity
- Conditions
- Adults Living with Overweight and Obesity
- Interventions
- First Posted Date
- 2025-06-23
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Wave Life Sciences Ireland Limited
- Target Recruit Count
- 34
- Registration Number
- 2024-520203-41-00
- Locations
- ๐ท๐ด
Spitalul Clinic Judetean De Urgenta Cluj, Cluj-Napoca, Romania
๐ท๐ดArensia Clinics S.R.L., Bucharest, Romania
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants with Pi*ZZ AATD
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06405633
- Locations
- ๐ฆ๐บ
St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
๐จ๐ฆDalhousie University - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
๐ซ๐ฎTurku University Hospital, Turku, Finland
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT06186492
- Locations
- ๐ฌ๐ง
Simbec-Orion Clinical Pharmacology,, Merthyr Tydfil, Wales, United Kingdom
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05683860
- Locations
- ๐ณ๐ฑ
Erasmus MC, Rotterdam, Netherlands
๐ณ๐ฑUniversitair Medisch Centrum Utrecht, Utrecht, Netherlands
๐ฌ๐งUniversity of Oxford - Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom
Study of WVE-003 in Patients With Huntington's Disease
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT05032196
- Locations
- ๐ฆ๐บ
Westmead Hospital, Westmead, New South Wales, Australia
๐ฆ๐บMonash Health, Clayton, Victoria, Australia
๐ฆ๐บRoyal Melbourne Hospital, Melbourne, Victoria, Australia
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT04931862
- Locations
- ๐ฆ๐บ
Macquarie University, North Ryde, New South Wales, Australia
๐ฆ๐บThe Wesley Hospital, Brisbane, Queensland, Australia
๐ฆ๐บPerron Institute, Nedlands, Western Australia, Australia
Open-label Study of WVE-N531 in Patients with Duchenne Muscular Dystrophy (FORWARD-53)
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT04906460
- Locations
- ๐ฏ๐ด
Istiklal Hospital/ Clinical Research Unit, Amman, Jordan
๐ฏ๐ดThe Specialty Hospital (TSH)/ Advanced Clinical Center, Amman, Jordan
๐ฌ๐งOxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT04617847
- Locations
- ๐ฆ๐บ
Westmead Hospital, Sydney, New South Wales, Australia
๐ฆ๐บRoyal Brisbane & Women's Hospital, Herston, Queensland, Australia
๐ฆ๐บRoyal Melbourne Hospital, Carlton, Victoria, Australia
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04617860
- Locations
- ๐ฆ๐บ
Westmead Hospital, Sydney, New South Wales, Australia
๐ฆ๐บRoyal Brisbane & Women's Hospital, Herston, Queensland, Australia
๐ฆ๐บRoyal Melbourne Hospital, Carlton, Victoria, Australia
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: WVE-210201 (suvodirsen)Drug: Placebo
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03907072
- Locations
- ๐บ๐ธ
Yale University, New Haven, Connecticut, United States
๐บ๐ธRare Disease Research, LLC., Atlanta, Georgia, United States
๐บ๐ธUniversity of Kansas Medical Center, Kansas City, Kansas, United States